Approval · Notice of Compliance 3240 · 1998
REZULIN: Notice of Compliance 3240
Issued April 6, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3240
- Date
- April 6, 1998
- Company
- Parke-Davis Division, Warner-Lambert Canada Inc.Scarborough, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: concomitatnt use with sulfonylureas in patients with type 2 diabetes - new strength
- Therapeutic class
- Antidiabetic agent, insulin resistance reducing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REZULIN | Not yet assigned | — |
| REZULIN | 02237531 | — |
Medicinal ingredients
- TROGLITAZONE 200 MG per TAB
- TROGLITAZONE 300 MG per TAB
- TROGLITAZONE 400 MG per TAB